NO20161568A1 - A new drug delivery system for treatment of cancer - Google Patents
A new drug delivery system for treatment of cancerInfo
- Publication number
- NO20161568A1 NO20161568A1 NO20161568A NO20161568A NO20161568A1 NO 20161568 A1 NO20161568 A1 NO 20161568A1 NO 20161568 A NO20161568 A NO 20161568A NO 20161568 A NO20161568 A NO 20161568A NO 20161568 A1 NO20161568 A1 NO 20161568A1
- Authority
- NO
- Norway
- Prior art keywords
- cancer
- treatment
- delivery system
- drug delivery
- new drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO20161568A NO342271B1 (en) | 2016-09-29 | 2016-09-29 | A new drug delivery system for treatment of cancer |
EP17784222.6A EP3518900A1 (en) | 2016-09-29 | 2017-09-29 | A new drug delivery system for treatment of disease |
US16/338,152 US20200023073A1 (en) | 2016-09-29 | 2017-09-29 | A new drug delivery system for treatment of disease |
PCT/EP2017/074798 WO2018060437A1 (en) | 2016-09-29 | 2017-09-29 | A new drug delivery system for treatment of disease |
CA3040016A CA3040016A1 (en) | 2016-09-29 | 2017-09-29 | A new drug delivery system for treatment of disease |
JP2019517040A JP2019529488A (en) | 2016-09-29 | 2017-09-29 | Novel drug delivery system for treating disease |
CN201780073657.2A CN110022860A (en) | 2016-09-29 | 2017-09-29 | For treating the new drug delivery system of disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO20161568A NO342271B1 (en) | 2016-09-29 | 2016-09-29 | A new drug delivery system for treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20161568A1 true NO20161568A1 (en) | 2018-03-30 |
NO342271B1 NO342271B1 (en) | 2018-04-30 |
Family
ID=62091609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20161568A NO342271B1 (en) | 2016-09-29 | 2016-09-29 | A new drug delivery system for treatment of cancer |
Country Status (1)
Country | Link |
---|---|
NO (1) | NO342271B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111989087A (en) * | 2018-03-27 | 2020-11-24 | 新泰福托特股份有限公司 | Poly (alkyl cyanoacrylate) nanoparticles for the treatment of cancer |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1701745A1 (en) * | 2003-12-22 | 2006-09-20 | Bracco Research S.A. | Gas-filled microvesicle assembly for contrast imaging |
US20110200530A1 (en) * | 2008-10-07 | 2011-08-18 | Bracco Research S.A. or Bracco Suisse S.A. | Targeting construct comprising anti-polymer antibody and contrast/therapeutic agents binding to the same |
WO2012094541A2 (en) * | 2011-01-05 | 2012-07-12 | The Regents Of The University Of California | Acoustically responsive particles with decreased cavitation threshold |
EP2508207A1 (en) * | 2011-03-31 | 2012-10-10 | BioAlliance Pharma | Nanoparticles loaded with chemotherapeutic antitumoral Drug |
US20130183244A1 (en) * | 2010-09-10 | 2013-07-18 | The Johns Hopkins University | Rapid Diffusion of Large Polymeric Nanoparticles in the Mammalian Brain |
US20140212502A1 (en) * | 2013-01-31 | 2014-07-31 | National Yang-Ming University | Nano- and micro-bubbles with ultrasound-triggered release and imaging functionalities |
WO2014191502A1 (en) * | 2013-05-28 | 2014-12-04 | Sinvent As | Process for preparing stealth nanoparticles |
-
2016
- 2016-09-29 NO NO20161568A patent/NO342271B1/en not_active IP Right Cessation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1701745A1 (en) * | 2003-12-22 | 2006-09-20 | Bracco Research S.A. | Gas-filled microvesicle assembly for contrast imaging |
US20110200530A1 (en) * | 2008-10-07 | 2011-08-18 | Bracco Research S.A. or Bracco Suisse S.A. | Targeting construct comprising anti-polymer antibody and contrast/therapeutic agents binding to the same |
US20130183244A1 (en) * | 2010-09-10 | 2013-07-18 | The Johns Hopkins University | Rapid Diffusion of Large Polymeric Nanoparticles in the Mammalian Brain |
WO2012094541A2 (en) * | 2011-01-05 | 2012-07-12 | The Regents Of The University Of California | Acoustically responsive particles with decreased cavitation threshold |
EP2508207A1 (en) * | 2011-03-31 | 2012-10-10 | BioAlliance Pharma | Nanoparticles loaded with chemotherapeutic antitumoral Drug |
US20140212502A1 (en) * | 2013-01-31 | 2014-07-31 | National Yang-Ming University | Nano- and micro-bubbles with ultrasound-triggered release and imaging functionalities |
WO2014191502A1 (en) * | 2013-05-28 | 2014-12-04 | Sinvent As | Process for preparing stealth nanoparticles |
Non-Patent Citations (9)
Title |
---|
Baghirov, Habib, et al. Focused ultrasound-mediated transport of poly(alkyl) cyanoacrylate nanoparticles across the blood-brain barrier in a melanoma brain metastasis model. Cancer Research, (2016) Vol. 76, No. 14, Supp. Supplement. Abstract Number: 2073. Meeting Info: 107th Annual Meeting of the American Association for Cancer Research, AACR 2016. New Orleans, LA, United States. 16 Apr 2016-20 Apr 2016. ISSN: 1538-7445, Dated: 01.01.0001 * |
Chaudhari K. R., et al. Targeting effiency and biodistribution of zoledronate conjugated docetaxel loaded PBCA nanoparticles for bone metastasis. Adv. Funct. Mater. 2012, 22, 4101-4114., Dated: 01.01.0001 * |
De Cock, Ine, et al. Sonoprinting and the importance of microbuble loading for the ultrasound mediated cellular delivery of nanoparticles. Biomaterials, 1 Mar 2016 Vol. 83, pp. 294-307. ISSN: 0142-9612; E-ISSN: 1878-5905., Dated: 01.01.0001 * |
Hansen, Rune; Stenstad, Per; Morch, Yrr. Ultrasound mediated delivery of a novel nanoparticle microbubble platform. Cancer Research, (15 Apr 2013) Vol. 73, No. 8, Supp. SUPPL. 1. Abstract Number: 5618. Meeting Info: 104th Annual Meeting of the American Association for Cancer Research, AACR 2013. Washington, DC, United States. 06 Apr 2013-10 Apr 2013. ISSN: 0008-5472 DIGITAL OBJECT ID: 10.1158/1538-7445.AM2013-5618., Dated: 01.01.0001 * |
Liu, Zhe et al. Iron oxide nanoparticle-containing microbubble composites as contrast agents for MR and ultrasound dual-modality imaging, Biomaterials (2011.05.05) vol. 32. no. 26. pp. 6155-6163., Dated: 01.01.0001 * |
Moon, Hyungwon, et al. Multifunctional theranostic contrast agent for photoacoustics- and ultrasound-based tumor diagnosis and ultrasound-stimulated local tumor therapy. Journal of Controlled Release, 28 Nov 2015 Vol. 218, pp. 63-71. ISSN: 0168-3659; E-ISSN: 1873-4995, Dated: 01.01.0001 * |
Morch, Yrr et al. Nanoparticle-stabilized microbubbles for multimodal imaging and drug delivery. Contrast Media and Molecular Imaging, (September/October 2015) Vol. 10, No. 5, pp. 356-366. ISSN: 1555-4309; E-ISSN: 1555-4317, Dated: 01.01.0001 * |
Wang, Jiayu, et al. A novel microbubble capable of ultrasound -triggered release of drug -loaded nanoparticles. Journal of Biomedical Nanotechnology, (March 2016) Vol. 12, No. 3, pp. 516-524. ISSN: 1550-7033; E-ISSN: 1550-7041, Dated: 01.01.0001 * |
Zhang, Yu et al.Preparation, characterization and biocompatability of poly(ethylene glycol)-poly(n-butyl cyanoacrylate) nanocapsules with oil core via miniemulsion polymerization. European Polymer Journal 44 (2008) 1654-1661, Dated: 01.01.0001 * |
Also Published As
Publication number | Publication date |
---|---|
NO342271B1 (en) | 2018-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL250660A0 (en) | Skin sensors for drug delivery devices | |
ZA201807048B (en) | Medical delivery system | |
EP3725349C0 (en) | Improved systems for medicine delivery | |
PT3139986T (en) | System for delivery of therapeutic gas | |
ZA201806819B (en) | Pharmaceutical combinations for the treatment of cancer | |
SG11202104923YA (en) | Pharmaceutical combination for treatment of cancer | |
LT3245988T (en) | System for ultrasound-enhanced transscleral delivery of drugs | |
ZA201900052B (en) | Pharmaceutical combinations for treating cancer | |
HUE057487T2 (en) | Drug delivery system | |
IL268416A (en) | Pharmaceutical combinations for treating cancer | |
GB201419540D0 (en) | Delivery of drugs | |
ZA201608820B (en) | Method for treating drug resistant cancer | |
IL246874A0 (en) | Drug delivery system | |
EP3720422C0 (en) | Liposomal system for drug delivery | |
ZA201907286B (en) | A pharmaceutical combination for the treatment of a cancer | |
PL3694585T3 (en) | Drug delivery apparatus | |
EP3471775A4 (en) | Hemoglobin-targeted drug delivery for the treatment of cancer | |
GB201710280D0 (en) | Drug delivery apparatus | |
NO20161568A1 (en) | A new drug delivery system for treatment of cancer | |
GB201520653D0 (en) | Apparatus for medicament delivery | |
IL275664A (en) | Drug delivery system | |
GB2559449B (en) | Hypoallergic drug delivery system | |
HK1259026A1 (en) | Localized delivery of anti-fugetactic agent for treatment of cancer | |
EP3720444A4 (en) | Drug delivery system for treating disease | |
GB201713936D0 (en) | Pharmaceutical combinations for the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |